The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days
in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin
(1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will
result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally,
the reduction in biomarkers of cellular pro-inflammatory state will be related to no change
in functional and patient reported outcomes.